Sildenafil Pharmathen 100 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sildenafil pharmathen 100 mg filmdragerad tablett

pharmathen s.a. - sildenafilcitrat - filmdragerad tablett - 100 mg - sildenafilcitrat 140,482 mg aktiv substans; laktosmonohydrat hjälpämne - sildenafil

Lekap 25 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lekap 25 mg filmdragerad tablett

jubilant pharmaceuticals nv - sildenafilcitrat - filmdragerad tablett - 25 mg - sildenafilcitrat 35,121 mg aktiv substans; laktosmonohydrat hjälpämne - sildenafil

Sildenafil Pharmathen 25 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sildenafil pharmathen 25 mg filmdragerad tablett

pharmathen s.a. - sildenafilcitrat - filmdragerad tablett - 25 mg - sildenafilcitrat 35,121 mg aktiv substans; laktosmonohydrat hjälpämne - sildenafil

Lekap 50 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

lekap 50 mg filmdragerad tablett

jubilant pharmaceuticals nv - sildenafilcitrat - filmdragerad tablett - 50 mg - laktosmonohydrat hjälpämne; sildenafilcitrat 70,241 mg aktiv substans - sildenafil

Sildenafil Pharmathen 50 mg Filmdragerad tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sildenafil pharmathen 50 mg filmdragerad tablett

pharmathen s.a. - sildenafilcitrat - filmdragerad tablett - 50 mg - laktosmonohydrat hjälpämne; sildenafilcitrat 70,241 mg aktiv substans - sildenafil

Blopresid Comp 16 mg/12,5 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

blopresid comp 16 mg/12,5 mg tablett

orifarm ab - hydroklortiazid; kandesartancilexetil - tablett - 16 mg/12,5 mg - kandesartancilexetil 16 mg aktiv substans; laktosmonohydrat hjälpämne; hydroklortiazid 12,5 mg aktiv substans - kandesartan och diuretika

Blopress Comp 16 mg/12,5 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

blopress comp 16 mg/12,5 mg tablett

cross pharma ab - hydroklortiazid; kandesartancilexetil - tablett - 16 mg/12,5 mg - hydroklortiazid 12,5 mg aktiv substans; kandesartancilexetil 16 mg aktiv substans; laktosmonohydrat hjälpämne - kandesartan och diuretika

Blopresid Comp 16 mg/12,5 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

blopresid comp 16 mg/12,5 mg tablett

medartuum ab - hydroklortiazid; kandesartancilexetil - tablett - 16 mg/12,5 mg - kandesartancilexetil 16 mg aktiv substans; hydroklortiazid 12,5 mg aktiv substans; laktosmonohydrat hjälpämne - kandesartan och diuretika

Blopresid Comp 16 mg/12,5 mg Tablett Sverige - svenska - Läkemedelsverket (Medical Products Agency)

blopresid comp 16 mg/12,5 mg tablett

paranova läkemedel ab - hydroklortiazid; kandesartancilexetil - tablett - 16 mg/12,5 mg - hydroklortiazid 12,5 mg aktiv substans; laktosmonohydrat hjälpämne; kandesartancilexetil 16 mg aktiv substans - kandesartan och diuretika

Riximyo Europeiska unionen - svenska - EMA (European Medicines Agency)

riximyo

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastiska medel - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. endast begränsade data finns tillgängliga om effekten och säkerheten för patienter som tidigare behandlats med monoklonala antikroppar inklusive rituximab eller patienter med refraktära mot tidigare rituximab plus kemoterapi. se avsnitt 5. 1 för ytterligare information. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab har visat sig minska risken för progression av ledskador mätt med röntgen och förbättra den fysiska funktionen, när det ges i kombination med metotrexat. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).